Bruce Kramer believed that researchers need to rethink the way they test new drugs on ALS patients like him.
He argued that the double-blind testing model doesn't work for a devastating fatal illness like ALS.
In this episode of Living While Dying, we also hear from a bio-ethicist about the decision to deny some patients access to an experimental drug.
MPR News is Member Supported
What does that mean? The news, analysis and community conversation found here is funded by donations from individuals. Make a gift of any amount during the Winter Member Drive to support this resource for everyone.